DEC 2017

InterAx achieves milestone that triggers second part of seed investment ahead of schedule

 

December 2017, Switzerland-Boston: InterAx announced today a successful milestone achievement to trigger the second part of the seed investment led by a team of Boston-based Biotech investors. Martin Ostermaier, CEO of InterAx said: “Our investors were impressed by the speed and quality of how the set goals for 2017 have been achieved, in particular with our success in identifying first hits in our in-house drug discovery program.”

SEP 2017

September 2017, Switzerland: 100 investors and experts selected InterAx as one of the most innovative and promising Swiss startup of the last 5 years! The seventh edition of the TOP 100 Swiss startup ranking was disclosed yesterday. As new entry, CEO Dr. Martin Ostermaier had the chance to pitch in front of more than 700 people, including more than 200 investors from Switzerland and abroad.

AUG 2017

InterAx and Prof. Peter Kolb from the Philipps-University Marburg initiated a collaboration for lead discovery

 

Villigen, Switzerland, 22nd of August 2017

InterAx Biotech AG, a Swiss start-up focusing on the discovery of novel GPCR-targeting medicines, and Prof. Peter Kolb of Philipps-University Marburg, group leader in the Department of Pharmaceutical Chemistry, entered a collaboration to fuse the unique biosensor and systems biology platform with the expertise on virtual screening for the development of lead compounds with highly tailored pharmacological properties for an undisclosed target.
 
About Prof. Peter Kolb, Department of Pharmaceutical Chemistry at Philipps-University Marburg
Peter Kolb is a Heisenberg Professor of Computer-Aided Drug Discovery. His research team works on the prediction and rational design of ligands with custom-tailored properties for a range of targets, predominantly from the GPCR family of membrane proteins. A key focus of this work is the synthetic accessibility of molecules, while at the same time focusing on novel, unprecedented scaffolds for the investigated receptors.
 
About InterAx
InterAx Biotech AG is a Swiss company and spinoff from the ETH Zurich and the Paul Scherrer Institute (PSI). InterAx is fully funded by private investors and is building a unique drug discovery platform for identification of functionally selective G protein-coupled receptor (GPCR) drug candidates. The InterAx core technology resides in engineering protein-based biosensors specifically sensing a particularly active state of a GPCR and in using computer algorithms to predict downstream cell signaling effects. This unique combination allows for better predictions of drug candidates properties for the desired GPCR target.

By combining the UMR unique expertise in virtual screening and the InterAx biosensor and systems biology platform, we will establish an iterative design and testing cycle that helps us guide the optimization of initial hits towards potent and efficacious lead matter. At the same time, we will elucidate potentially paradigm-changing principles that will aid us in future endeavors.

 

AUG 2017

InterAx welcomes Prof. Dr. Michel Bouvier as new Advisory Board Member

 

August 2017, Switzerland-Canada

 

Scientific advisory boards set the bar for the quality of research and development performed in big pharma, medium biotech and small start-ups. Their excellence is a measure for scientific standards and innovation in an enterprise. They provide insights into scientific trends from an international perspective, give strategic advice for the company’s R&D plans and consolidate technological leadership. InterAx Biotech AG, a spin-off of the Paul Scherrer Institute (PSI), has strengthened its scientific advisory board with one of the most internationally cited scientists, Prof. Michel Bouvier from the University of Montréal.


Professor Bouvier is Chief Executive Officer of the Institute for Research in Immunology and Cancer (IRIC) and professor in the Department of Biochemistry and Molecular Medicine at the Faculty of Medicine of the University of Montreal. His research focuses on deciphering the molecular mechanisms that regulate one of the most important classes of current drug targets, the family of G protein-coupled receptors (GPCRs). Many of his groundbreaking findings have over the years led to significant paradigm shifts in the field and paved the way for alternative strategies to develop novel and safer drugs targeting GPCRs. In his role as a scientific advisor, he will advise InterAx Biotech in the development of the company’s proprietary novel biosensors. These biosensors are the core pillar of the InterAx GPCR lead discovery platform that combines biosensors with Computational Biology for quantitative comparison of drug-induced GPCR signaling. InterAx unique drug discovery platform will dramatically reduce costs for the development of novel GPCR drugs with reduced side effects, thereby benefiting patients with unmet medical needs.

In his Interview to PARK INNOVAARE, Professor Bouvier explains what caught his interest in this Swiss start-up and how he sees its development in years to come.

PARK INNOVAARE: Why did you decide to join InterAx’ Scientific Advisory Board?

During a visit at PSI, I had the opportunity to meet the scientific team of InterAx. I was impressed by the innovative nature of the biosensors developed by the team and by the potential of both the technology and InterAx’ scientists. The technology developed by InterAx is complementary to biosensor’s technology that I myself developed and I saw a great potential for synergy.

Where do you see the potential for InterAx’ technology?

The recent emergence of the concepts of GPCR functional selectivity and ligand-biased signaling applied to the discovery of more efficient and safer drugs targeting these receptors created a need for technologies probing the different activation modalities of the receptors. The biosensors developed by InterAx provide a new set of tools that will allow the identification of modalities associated with desired therapeutic outcomes.

How can your extensive knowledge and expertise help InterAx develop?

Given my long-standing expertise in GPCR signaling, I can advise InterAx’s scientists on the diverse aspects of GPCR signaling and their pharmacological modulation for therapeutic discovery. Based on my knowledge of the market’s need I will also help InterAx team prioritizing the value-added projects. I will also use my extended relationship network with academia and industry to identify possible collaborators and partners that could synergize with InterAx to reach their objectives.

FEB 2017

We welcome our new CSO Maria Waldhoer!

 

February 2017, Switzerland : Dr. Maria Waldhoer recently joined our team as Chief Scientific Officer. She has a track record of more than 20 years in GPCR / 7TM receptor signaling and pharmacology both in academia and industry. She brings in a wealth of expertise and knowledge in drug discovery for GPCRs.